Comparative Pharmacology
Head-to-head clinical analysis: DETROL LA versus SANCTURA XR.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DETROL LA versus SANCTURA XR.
DETROL LA vs SANCTURA XR
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Tolterodine is a competitive muscarinic receptor antagonist. It blocks acetylcholine binding at muscarinic receptors (M1–M5), reducing detrusor muscle contraction and bladder pressure, thereby increasing bladder capacity and decreasing urinary frequency.
Trospium is an antimuscarinic agent that competitively inhibits acetylcholine at muscarinic receptors, reducing bladder detrusor muscle contractions.
4 mg orally once daily; may be reduced to 2 mg once daily based on tolerability.
60 mg orally once daily, taken with a full glass of water at least 1 hour before meals. Extended-release capsule.
None Documented
None Documented
Terminal elimination half-life is approximately 7 hours (range 5-10 hours) for the extended-release formulation, allowing once-daily dosing.
Terminal elimination half-life is approximately 7-10 hours in patients with normal renal function; prolonged to 20-30 hours in moderate to severe renal impairment.
Approximately 77% eliminated in urine (primarily as metabolites, <1% unchanged) and 17% in feces.
Primarily renal excretion (70-80% as unchanged drug and active metabolite); approximately 10% fecal; 5-10% biliary.
Category C
Category C
Anticholinergic
Anticholinergic